Aficamten 治疗梗阻性肥厚型心肌病的 2 期研究
Aficamten 显著降低静息和 Valsalva 动作后的左心室流出道压差,并适度降低射血分数,同时改善症状和生物标志物,不良事件与安慰剂相似。
要点
- Aficamten 显著降低梗阻性 HCM 患者的 LVOT 压差。
- 治疗中射血分数适度下降,需监测心功能。
- 症状和 NT-proBNP 改善,不良事件与安慰剂相似。
核心结论
- Aficamten 可大幅降低 oHCM 患者的 LVOT 压差,多数患者生物标志物和症状改善。
- 结果提示靶向肌节治疗用于 oHCM 的潜力。
研究设计与样本
- 2 期随机双盲安慰剂对照研究,纳入 oHCM 且静息 LVOT 压差≥30 mm Hg 或 Valsalva 后≥50 mm Hg 的患者。
- 剂量根据压差和射血分数滴定。
主要发现
- 从基线至 10 周,aficamten 降低静息压差:队列 1 平均差 -40 ± 27 mm Hg(P=0.0003 vs 安慰剂),队列 2 -43 ± 37 mm Hg(P=0.0004 vs 安慰剂)。
- 降低 Valsalva 压差:队列 1 -36 ± 27 mm Hg(P=0.001 vs 安慰剂),队列 2 -53 ± 44 mm Hg(P<0.0001 vs 安慰剂)。
- 射血分数适度降低:队列 1 -6% ± 7.5%(P=0.007 vs 安慰剂),队列 2 -12% ± 5.9%(P<0.0001 vs 安慰剂)。
- NYHA 心功能分级改善≥1 级:安慰剂组 31%,队列 1 43%,队列 2 64%(无统计学显著性)。
- 与安慰剂相比,aficamten 使 NT-proBNP 相对降低 62%(P=0.0002)。
关键数值与推荐
- 入组标准:oHCM 且静息 LVOT 压差≥30 mm Hg 或 Valsalva 后≥50 mm Hg。
- 主要安全性和有效性评估包括压差、射血分数、NYHA 分级和心脏生物标志物。
临床怎么用
- 对于 oHCM 患者,aficamten 可作为降低 LVOT 压差和改善症状的潜在选择。
- 治疗期间需根据压差和射血分数滴定剂量,并监测射血分数变化。
- 不良事件与安慰剂相似,未出现治疗中断。
局限性
- 症状改善未达统计学显著性。
- 剂量探索分两个队列,结果解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients. OBJECTIVES: This study aims to evaluate the safety and efficacy of aficamten in patients with oHCM. METHODS: Patients with oHCM and LVOT gradients ≥30 mm Hg at rest or ≥50 mm Hg with Valsalva were randomized 2:1 to receive aficamten (n = 28) or placebo (n = 13) in 2 dose-finding cohorts. Doses were titrated based on gradients and ejection fraction (EF). Safety and changes in gradient, EF, New York Heart Association functional class, and cardiac biomarkers were assessed over a 10-week treatment period and after a 2-week washout. RESULTS: From baseline to 10 weeks, aficamten reduced gradients at rest (mean difference: -40 ± 27 mm Hg, and -43 ± 37 mm Hg in Cohorts 1 and 2, P = 0.0003 and P = 0.0004 vs placebo, respectively) and with Valsalva (-36 ± 27 mm Hg and -53 ± 44 mm Hg, P = 0.001 and <0.0001 vs placebo, respectively). There were modest reductions in EF (-6% ± 7.5% and -12% ± 5.9%, P = 0.007 and P < 0.0001 vs placebo, respectively). Symptomatic improvement in ≥1 New York Heart Association functional class was observed in 31% on placebo, and 43% and 64% on aficamten in Cohorts 1 and 2, respectively (nonsignificant). With aficamten, N-terminal pro-B-type natriuretic peptide was reduced (62% relative to placebo, P = 0.0002). There were no treatment interruptions and adverse events were similar between treatment arms. CONCLUSIONS: Aficamten resulted in substantial reductions in LVOT gradients with most patients experiencing improvement in biomarkers and symptoms. These results highlight the potential of sarcomere-targeted therapy for treatment of oHCM.
引用
- Maron MS, Masri A, Choudhury L, et al. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023. PMID: 36599608. doi:10.1016/j.jacc.2022.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。